



## Cerevel Therapeutics Holdings, Inc (CERE US)

### COMPANY DESCRIPTION

Founded in 2018, Cerevel Therapeutics Holdings, Inc is a clinical-stage biopharmaceutical company that focuses on neuroscience diseases headquartered in Cambridge, MA. Cerevel Therapeutics has four lead programs that target schizophrenia, epilepsy, and Parkinson's disease, respectively. Bain Capital and Pfizer own, collectively, ca. 59.6% of the company. 🚀

### BUSINESS MODEL


Cerevel Therapeutics has not generated any revenue from product sales to date. 🚀

### REVERSE MERGER IPO HISTORY


On 10/28/2020, Cerevel Therapeutics Holdings Inc completed business combination with the special purpose acquisition company ARYA Sciences Acquisition Corp II (Arya II) and began trading on the Nasdaq Capital Market. The merger was first announced on 7/29/2020. Cerevel Therapeutics fell on first day to \$9.88 (▼2.18%). 🚀

Cerevel Therapeutics Holdings, Inc was included in the IPOX® 100 U.S. Index (ETF: FPX US, FPX LN) on 09/20/2021 and currently weighs ca. 0.20% of the portfolio. 🚀

### HISTORICAL PERFORMANCE



### GROWTH OUTLOOK



| Compound                        | Disease Area                 | Discovery | Pre-clinical | Phase 1 | Phase 2 | Phase 3 | Upcoming Milestones | Mechanism                    |
|---------------------------------|------------------------------|-----------|--------------|---------|---------|---------|---------------------|------------------------------|
| <b>Lead Programs</b>            |                              |           |              |         |         |         |                     |                              |
| Enracidine                      | Schizophrenia / Psychosis    |           |              |         |         |         | Ph. 2 Data 1H 2024  | M4 PAM                       |
| Dasigabat                       | Epilepsy                     |           |              |         |         |         | Ph. 2 Data 2H 2023  | GABA <sub>A</sub> α2/3/5 PAM |
| Dasigabat                       | Anxiety                      |           |              |         |         |         | Pending             |                              |
| Tarapadon                       | Early Parkinson's            |           |              |         |         |         | Ph. 3 Data 2H 2023  | D1/D5 Strong Partial Agonist |
| Tarapadon (adjunct with L-Dopa) | Late Parkinson's             |           |              |         |         |         | Ph. 3 Data 1H 2023  |                              |
| CVL-871                         | Dementia-related Agitation   |           |              |         |         |         | Ph. 2a Data 1H 2023 | D1/D5 Partial Agonist        |
| <b>Other Programs</b>           |                              |           |              |         |         |         |                     |                              |
| CVL-354                         | MDD / Substance Use Disorder |           |              |         |         |         | Ph. 1 Data          | KOR Antagonist               |
| CVL-047                         | MDD / Schizophrenia          |           |              |         |         |         | Ph. 1 Data          | PDE4 Inhibitor               |
| M4 Agonist                      | Schizophrenia / Psychosis    |           |              |         |         |         | Candidate Selection | M4 Agonist                   |
| CVL-936                         | Substance Use Disorder       |           |              |         |         |         | Under Evaluation    | D3 Preferring Antagonist     |
| LRRK2 Inhibitor                 | Parkinson's                  |           |              |         |         |         | Candidate Selection | LRRK2 Inhibitor              |

### INDUSTRY COMPARISON

| COMPANY                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | STOCK SYMBOL | IPO/SPIN-OFF DATE                                                                                 | INITIAL RETURN | OFFER TO DATE (TR) | 2022 YTD | BETA TO BENCHMARK | R&D EXPENSE (Millions) | DILUTED EPS | CASH BURN                                             |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|---------------------------------------------------------------------------------------------------|----------------|--------------------|----------|-------------------|------------------------|-------------|-------------------------------------------------------|
| cerevel                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           | CERE US      | Cerevel Therapeutics merged with ARYBU on 10/28/2020 at an implied equity value of \$780 million. |                |                    | -11.20%  | 0.98              | \$180.32               | -\$1.65     | 30.35 (cash expected to support operations into 2024) |
| Competitors include pharmaceutical and biotechnology companies such as Otsuka Holdings, Johnson & Johnson, Alkermes, Eli Lilly, Allergan, Intra-Cellular Therapies, Sumitomo Dainippon Pharma, Acadia Pharmaceuticals, Minerva Neurosciences, Neurocrine Biosciences, Karuna Therapeutics, Xenon Pharmaceuticals, Sage Therapeutics, Marinus Pharmaceuticals, VistaGen Therapeutics, Zogenix (acquired by UCB), GW Pharmaceuticals (acquired by Jazz Pharmaceuticals), Medtronic Inc, St. Jude Medical, Denali, Prothena, Roche, Voyager Therapeutics, Prevail Therapeutics, AstraZeneca, and IRLAB Therapeutics. |              |                                                                                                   |                |                    |          |                   |                        |             |                                                       |